Update Note: This article reports new information involving Dr. Heidi Overton's nomination to lead the Food and Drug Administration following MedicalDaily's earlier coverage. The latest development, reported by STAT on September 29, 2026, is that the Senate health committee has no vote scheduled before the Senate leaves for the midterm elections.
The Senate health committee is not expected to vote on Dr. Heidi Overton's nomination as FDA commissioner before the November midterm elections, STAT reported. This is the Senate's last week in session until November 9, and Overton was not included in the committee's September 30 vote on three other health nominees.
That means the agency responsible for approving medicines, policing food safety, and reviewing vaccines will go at least into mid-November without a Senate-confirmed leader. Acting Commissioner Kyle Diamantas has run the FDA since May.
For households, the delay is less about one person than about steadiness. Pending decisions on new drugs, recalls, and vaccine policy continue, but major shifts in direction tend to wait for permanent leadership.
A Vote Pushed Past Election Day
The committee, formally the Senate Health, Education, Labor and Pensions Committee, held Overton's confirmation hearing on September 24. STAT reported that the hearing did not clarify how undecided Republicans would vote, and that it would take just one Republican to sink her nomination in committee.
Chair Bill Cassidy of Louisiana, a physician, has not committed. In August, he called Overton's role in a White House executive order that reduced the number of recommended childhood vaccines "almost disqualifying," Punchbowl News reported. The day before the hearing, he said, "I'm trying to be neutral in my preconception."
Sen. Lisa Murkowski of Alaska described Overton as "well rehearsed in her responses" and remained undecided, according to Roll Call. Roll Call also reported that Cassidy declined to say whether he would support Overton or hold a vote before the end of the year.
Acting Leadership at the FDA Since May
The FDA has lacked a confirmed commissioner since Dr. Marty Makary resigned on May 12 amid reported White House frustration over delays related to flavored vaping products. Diamantas, a lawyer who previously served as deputy commissioner for food, stepped in as acting head, HCPLive reported.
Acting leaders have full legal authority to run the agency day to day. Drug reviewers keep working against statutory deadlines, and inspectors and recall staff continue their routine work. What is harder without a confirmed head is setting long-term priorities, defending budget requests, and making politically sensitive decisions with lasting effects.
Several such decisions are pending, including the future of rules on the abortion pill mifepristone and how the agency handles vaccine reviews after the White House executive order. Overton told senators she would "follow statutory guidelines" and "review the evidence" on many of these questions without committing to specific outcomes.
Earlier Hearing Testimony and What Is Different Now
MedicalDaily previously reported that Overton told senators the MMR vaccine is safe and not lethal as the nation faced its worst measles year in more than three decades. The CDC has since reported 3,659 confirmed measles cases as of September 24. That hearing focused on what she said. The new development is about timing, and about what the agency looks like while senators wait.
The delay does not mean the nomination has failed, and neither party has announced a formal effort to defeat it. It does mean the FDA will head into the fall and winter respiratory virus season, a busy period for vaccine decisions, under acting leadership.
It also extends a broader pattern of vacancies in federal health posts. The country still has no confirmed surgeon general. The committee advanced Dr. Nicole Saphier, the administration's third pick for the post, on September 30, but she still needs a vote by the full Senate.
Overton's own background shapes the stakes. She is a physician who earned her medical degree at the University of New Mexico and a doctorate from Johns Hopkins, and she currently serves as deputy assistant to the president for domestic policy, ABC News reported. Critics, including Cassidy, have focused on her role in the White House vaccine schedule order.
At the hearing, Overton also told Sen. Maggie Hassan of New Hampshire, "I have not seen any causal evidence that Tylenol causes autism." That answer matters to pregnant patients and parents who have encountered conflicting claims about acetaminophen.
Household Decisions That Do Not Change
Readers do not need to change any health decision because of the vote delay. FDA-approved medicines remain approved, and prescriptions, vaccines, and food recall notices continue as usual. Overton herself told the committee, "Every vaccine on the U.S. market right now is safe and effective according to the FDA."
Families who follow FDA recalls should keep checking the agency's recall listings and their state health department alerts, which are unaffected by who holds the top job. Patients waiting on a drug that is under FDA review can ask their doctor or the manufacturer about the expected decision date, since review deadlines are set by law.
The next clear milestone is the Senate's return on November 9. A committee vote could come after that, and the outcome is not predictable. Until then, the FDA's most consequential policy choices are likely to wait, while day-to-day safety work continues.
Key Questions Answered
Will the Senate vote on Heidi Overton before the midterms? A committee vote is not expected before the Senate returns on November 9, according to STAT.
Who is running the FDA now? Acting Commissioner Kyle Diamantas, who has led the agency since Dr. Marty Makary resigned in May.
Why is the vote on hold? Key Republicans, including Chair Bill Cassidy and Sen. Lisa Murkowski, have not said how they will vote.
Does this affect my medications or vaccines? No. Approved products remain approved, and routine reviews and recalls continue.
Could her nomination still be approved? Yes. The delay does not decide the outcome, and a vote could come after the Senate returns.
What did Overton say about vaccines? She told senators every vaccine on the U.S. market is safe and effective according to the FDA.
Published by Medicaldaily.com
